Additionally, administration of BA sequestrants or FXR agonists significantly prevented HCC development, suggesting a potential strategy of targeting dysregulated BAs levels for the treatment of patients with HCC, especially those with abnormally high BAs (54, 55). The gene discussed is NR1H4; the disease is hepatocellular carcinoma.